Pembrolizumab in Elderly Patients With Advanced Lung Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-15
Target enrollment:
Participant gender:
Summary
This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects
older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed
death-ligand 1 (PD-L1). 82 patients will be enrolled in this trial to examine the efficacy,
the impact on geriatric assessments, the quality of life and the self-reported outcomes.